Angioplasty in Nonagenarians Is Increasingly Frequent: How Does It Evolve?

Currently, the number of nonagenarian patients undergoing angioplasty (whether elective, urgent or emergency) has increased. 

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

This population is linked to more comorbidities and has barely been included in most randomized studies or registries. As such, we do not have robust evidence on this group.

Researchers conducted an analysis of the J-PCI OUTCOME Registry, in which patients were divided according to their age into 4 groups: 60-69 years (13,155 patients: 32.3%); 70-79 years (16,874: 41.4%); 80-89 years (9813: 24.1%), and ≥90 years (88: 2.2%).

Compared with younger patients, the group of nonagenarians was comprised mostly of females (54%) with lower rates of diabetes, hypertension, dyslipidemia, smoking, and cardiac and renal failure. However, this group was linked to higher rates of acute coronary syndromes, left main coronary artery disease, and three-vessel lesions.

Transradial access was the least employed access in this group, and there were no differences between groups in the use of stents and drug-eluting balloons, procedure time, or bleeding in the access site. Nonetheless, there were more instances of bleeding unrelated to the access site compared with the rest of the groups.

Read also: TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

After a 1-year follow-up, mortality and bleeding rates were higher in nonagenarian patients compared with younger patients (1.5x higher than in octogenarians).

Cardiovascular death, infarction, and stroke in patients ≥90 years old were 13.5%, 8.1%, and 6.8%, respectively, after a 1-year follow-up. Furthermore, these patients had higher rates of fatal acute coronary syndromes, heart failure, and major bleeding.

The predictors of MACE at 1 year were cardiogenic shock, cardiac arrest, and anticoagulant use.

Conclusion

Currently, nonagenarians undergoing angioplasty continue to experience a considerable increased risk of adverse cardiovascular events, which reduces their survival. In addition, they present severe injuries with adverse events including increased rates of MACE, death, and major bleeding, occurring 1.5x more often in nonagenarian patients than in octogenarians.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: One-year outcome after percutaneous coronary intervention in nonagenarians: Insights from the J-PCI OUTCOME registry.

Reference: Kanichi Otowa, et al. Am Heart J 2022;246:105–116.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...